<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152696</url>
  </required_header>
  <id_info>
    <org_study_id>2000023590</org_study_id>
    <secondary_id>2U10HD055925-06</secondary_id>
    <nct_id>NCT02152696</nct_id>
  </id_info>
  <brief_title>Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location</brief_title>
  <acronym>ACTorNOT</acronym>
  <official_title>Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to compare three currently available management&#xD;
      strategies for women with a persisting pregnancy of unknown location (PPUL), which makes them&#xD;
      at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a confirmed&#xD;
      PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by&#xD;
      methotrexate (MTX) for some (those that have evidence of a non visualized ectopic pregnancy)&#xD;
      2) Empiric treatment with MTX for all 3) Expectant management. Randomization will be 1:1:1&#xD;
      into these three arms. After randomization, they will be followed and treated clinically as&#xD;
      is indicated by the progression of their condition. Primary outcome measures: uneventful&#xD;
      decline of hCG to 5 IU/mL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2014</start_date>
  <completion_date type="Actual">August 19, 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy</measure>
    <time_frame>6 weeks from randomization</time_frame>
    <description>The primary outcome measure in each of each 3 treatment arm is the uneventful clinical resolution of a PPUL without change in treatment from the initial management strategy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Persistent Pregnancy of Unknown Location</condition>
  <condition>Ectopic Pregnancy</condition>
  <arm_group>
    <arm_group_label>Expectant Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will have their PPUL expectantly managed using serum hCG monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uterine evacuation with MTX for some</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empiric treatment with MTX for all</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.</description>
    <arm_group_label>Empiric treatment with MTX for all</arm_group_label>
    <arm_group_label>Uterine evacuation with MTX for some</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Uterine Evacuation</intervention_name>
    <description>Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.</description>
    <arm_group_label>Uterine evacuation with MTX for some</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Expectant Management</intervention_name>
    <description>Pregnancy will be expectantly managed using serum hcg monitoring</description>
    <arm_group_label>Expectant Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female with a persisting pregnancy of unknown location:&#xD;
&#xD;
          -  A pregnancy of unknown location is defined as a pregnancy in a woman with a positive&#xD;
             pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on&#xD;
             ultrasound imaging. A definitive sign of gestation includes ultrasound visualization&#xD;
             of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in&#xD;
             the adnexa. Ultrasound must be performed within 7 days prior to randomization.&#xD;
&#xD;
          -  Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days),&#xD;
             showing &lt; 15% rise per day, or &lt; 50% fall between the first and last value.&#xD;
&#xD;
          -  Patient is hemodynamically stable, hemoglobin &gt;10 mg/dL&#xD;
&#xD;
          -  Greater than or 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamically unstable in need of acute treatment&#xD;
&#xD;
          -  Most recent hCG &gt; 5000 mIU/mL&#xD;
&#xD;
          -  Patient obtaining care in relation to a recently completed pregnancy (delivery,&#xD;
             spontaneous or elective abortion)&#xD;
&#xD;
          -  Diagnosis of gestational trophoblastic disease&#xD;
&#xD;
          -  Subject unwilling or unable to comply with study procedures&#xD;
&#xD;
          -  Known hypersensitivity to MTX&#xD;
&#xD;
          -  Presence of clinical contraindications for treatment with MTX&#xD;
&#xD;
          -  Prior medical or surgical management of this gestation&#xD;
&#xD;
          -  Subject unwilling to accept a blood transfusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Eisenberg, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Barnhart, MD MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Diamond, MD</last_name>
    <role>Study Director</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Legro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelle Cedars, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Steiner, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Hansen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Coutifaris, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heping Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - Women's Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>October 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy, Ectopic</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared with other researchers through the NICHD DASH system. It will be available 6 months after publication of the primary results.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02152696/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Expectant Management</title>
          <description>Subjects will have their PPUL expectantly managed using serum hCG monitoring.&#xD;
Expectant Management: Pregnancy will be expectantly managed using serum hcg monitoring</description>
        </group>
        <group group_id="P2">
          <title>Uterine Evacuation With MTX for Some</title>
          <description>Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.&#xD;
Uterine Evacuation: Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.</description>
        </group>
        <group group_id="P3">
          <title>Empiric Treatment With MTX for All</title>
          <description>Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Expectant Management</title>
          <description>Subjects will have their PPUL expectantly managed using serum hCG monitoring.&#xD;
Expectant Management: Pregnancy will be expectantly managed using serum hcg monitoring</description>
        </group>
        <group group_id="B2">
          <title>Uterine Evacuation With MTX for Some</title>
          <description>Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.&#xD;
Uterine Evacuation: Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.</description>
        </group>
        <group group_id="B3">
          <title>Empiric Treatment With MTX for All</title>
          <description>Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="5.6"/>
                    <measurement group_id="B2" value="31.2" spread="5.9"/>
                    <measurement group_id="B3" value="31.5" spread="5.7"/>
                    <measurement group_id="B4" value="31.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated gestational age - week</title>
          <population>Data were missing for 1 patient in the Expectant management group, 4 in the Uterine evacuation with MTX for some group and 2 in the Empiric treatment with MTX for all.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="85"/>
                    <count group_id="B2" value="83"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" spread="1.8"/>
                    <measurement group_id="B2" value="6.9" spread="1.9"/>
                    <measurement group_id="B3" value="6.7" spread="2.0"/>
                    <measurement group_id="B4" value="6.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First hCG value at screening (mIU/ml)</title>
          <units>mIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="86"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="82"/>
                    <count group_id="B4" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="661.2" spread="688.6"/>
                    <measurement group_id="B2" value="561.9" spread="702.5"/>
                    <measurement group_id="B3" value="633.3" spread="695.8"/>
                    <measurement group_id="B4" value="618.3" spread="694.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy</title>
        <description>The primary outcome measure in each of each 3 treatment arm is the uneventful clinical resolution of a PPUL without change in treatment from the initial management strategy.</description>
        <time_frame>6 weeks from randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Expectant Management</title>
            <description>Subjects will have their PPUL expectantly managed using serum hCG monitoring.&#xD;
Expectant Management: Pregnancy will be expectantly managed using serum hcg monitoring</description>
          </group>
          <group group_id="O2">
            <title>Uterine Evacuation With MTX for Some</title>
            <description>Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.&#xD;
Uterine Evacuation: Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.</description>
          </group>
          <group group_id="O3">
            <title>Empiric Treatment With MTX for All</title>
            <description>Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy</title>
          <description>The primary outcome measure in each of each 3 treatment arm is the uneventful clinical resolution of a PPUL without change in treatment from the initial management strategy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The period of time over which the adverse events were collected is: from the initiation of the study procedures to the end of the study treatment follow-up, which is about an average of 42 days following the last administration of study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Expectant Management</title>
          <description>Subjects will have their PPUL expectantly managed using serum hCG monitoring.&#xD;
Expectant Management: Pregnancy will be expectantly managed using serum hcg monitoring</description>
        </group>
        <group group_id="E2">
          <title>Uterine Evacuation With MTX for Some</title>
          <description>Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.&#xD;
Uterine Evacuation: Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.</description>
        </group>
        <group group_id="E3">
          <title>Empiric Treatment With MTX for All</title>
          <description>Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.&#xD;
Methotrexate: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalization.ED visit pelvic ultrasound revealed right adnexal mass concerning for tubal pregnancy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Salpingectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Right ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="86"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="87"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="86"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="87"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Mouth Sores</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="87"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>One or more adverse event</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="86"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="87"/>
                <counts group_id="E3" events="46" subjects_affected="46" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Heart Burn/Indigestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hair Loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="86"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="87"/>
                <counts group_id="E3" events="36" subjects_affected="36" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dizziness or weakness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="86"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="87"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Shoulder or back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Persistent dry cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Any Other Side Effects</sub_title>
                <description>Including sore throats, cough, constipation, depression, lower back pain, pain in breasts/shoulder, and other unspecified events. These events were recorded in free text, not separated.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="86"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="87"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="86"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="87"/>
                <counts group_id="E3" events="38" subjects_affected="38" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="86"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="87"/>
                <counts group_id="E3" events="39" subjects_affected="39" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heping Zhang, PhD</name_or_title>
      <organization>Yale University</organization>
      <phone>203-785-5185</phone>
      <email>heping.zhang@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

